Xiaoqi Pan

Dr. Xiaoqi Pan


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 December 2022 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
QLQiuju Li
Qiuju Li
FPFu PENG
Fu PENG
XYXiaoyu Yan
Xiaoyu Yan
YCYan Chen
Yan Chen
JZJie Zhou
Jie Zhou
XPXiaoqi Pan
Xiaoqi Pan

1 January 2020 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
XPXiaoqi Pan
Xiaoqi Pan
XMXiao Ma
Xiao Ma
YJYinxiao Jiang
Yinxiao Jiang
JWJianxia Wen
Jianxia Wen
LYLian Yang
Lian Yang
CPCheng Peng
Cheng Peng
Liver fibrosis resulting from continuous long‐term hepatic damage represents a heavy burden worldwide. Liver fibrosis is recognized as a complicated pathogenic mechanism with extracellular matrix (ECM) accumulation and hepatic stellate cell (HSC) activation. A series of drugs demonstrate significant antifibrotic activity in vitro and in vivo. No specific agents with ideally clinical efficacy for liver fibrosis treatment have been developed. In this review, we summarized the antifibrotic effects and molecular mechanisms of 29 kinds of common natural products. The mechanism of these compounds is correlated with anti‐inflammatory, antiapoptotic, and antifibrotic activities. Moreover, parenchymal hepatic cell survival, HSC deactivation, and ECM degradation by interfering with multiple targets and signaling pathways are also involved in the antifibrotic effects of these compounds. However, there remain two bottlenecks for clinical breakthroughs. The low bioavailability of natural products should be improved, and the combined application of two or more compounds should be investigated for more prominent pharmacological effects. In summary, exploration on natural products against liver fibrosis is becoming increasingly extensive. Therefore, natural products are potential resources for the development of agents to treat liver fibrosis.

1 September 2021 in Toxicology Letters
Verified
Journal Article
Closed access
LYLiang Yang
Liang Yang
YCYan Chen
Yan Chen
JZJie Zhou
Jie Zhou
JSJiayi Sun
Jiayi Sun
WJWanyanhan Jiang
Wanyanhan Jiang
XPXiaoqi Pan
Xiaoqi Pan

19 October 2022 in Frontiers in Pharmacology
Verified
Journal Article
Open access
XYXiaoyu Yan
Xiaoyu Yan
QLQiuju Li
Qiuju Li
LJLin Jing
Lin Jing
SWShuangyue Wu
Shuangyue Wu
WDWei Duan
Wei Duan
XPXiaoqi Pan
Xiaoqi Pan
Phyllanthi Fructus (PF), the edible fruits of Phyllanthus emblica L., serves as an important resource for some health products, foods and drugs due to its high safety and sufficient nutritional value. In recent years, in vivo and in vitro experiments have been conducted to reveal the active components of PF. More than 180 compounds have been isolated and identified from the PF so far, primarily including tannins, phenolic acids, flavonoids, terpenoids, polysaccharides, fatty acids and amino acids. In traditional Chinese medicine (TCM), PF is used to cure several diseases such as bronchitis, asthma, diabetes, peptic ulcer, hepatopathy, leprosy, and jaundice. Consistent with ethnopharmacology, numerous modern studies have demonstrated that the extracts or monomeric compounds derived from PF exhibit various pharmacological effects including anti-oxidation, anti-bacteria, anti-inflammation, anti-tumour, anti-virus, immunity improvement, hypoglycemic and hypolipidemic effects, and multiple organ protective protection. Toxicological studies on PF indicated the absence of any adverse effects even at a high dose after oral administration. Due to strict quality control, these pharmacological activities and the safety of PF greatly improve the development and utilization of products. Our comprehensive review aims to summarize the phytochemistry, pharmacological effects, toxicology, and product development of PF to provide theoretical guidance and new insights for further research on PF in the future.

1 January 2022 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
WWWenlin Wang
Wenlin Wang
JJJialuo Jiang
Jialuo Jiang
YHYan Huang
Yan Huang
FPFu PENG
Fu PENG
THTingting Hu
Tingting Hu
RCRao Chaolong
Rao Chaolong

Verified
Journal Article
Open access
PDF file
FPFu PENG
Fu PENG
HFHuali Fan
Huali Fan
SLsui li
sui li
CPCheng Peng
Cheng Peng
XPXiaoqi Pan
Xiaoqi Pan
In the last decades, a kind of small non-coding RNA molecules, called as microRNAs, has been applied as negative regulators in various types of cancer treatment through down-regulation of their targets. More recent studies exert that microRNAs play a critical role in the EMT process of cancer, promoting or inhibiting EMT progression. Interestingly, accumulating evidence suggests that pure compounds from natural plants could modulate deregulated microRNAs to inhibit EMT, resulting in the inhibition of cancer development. This small essay is on the purpose of demonstrating the significance and function of microRNAs in the EMT process as oncogenes and tumor suppressor genes according to studies mainly conducted in the last four years, providing evidence of efficient target therapy. The review also summarizes the drug candidates with the ability to restrain EMT in cancer through microRNA regulation.